Using blood tests to predict infections after kidney stone surgery
Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.
This study is testing if blood tests can help predict which adults are more likely to get infections after kidney stone surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Miami Academic / other |
| Locations | 1 site (Miami, Florida) |
| Trial ID | NCT04669886 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop a risk stratification system for predicting postoperative infectious complications and systemic inflammatory responses in patients undergoing percutaneous nephrolithotomy (PCNL). By analyzing pre-and post-operative blood endotoxin levels, the researchers hope to identify patients at higher risk for infections. The study will involve adults scheduled for PCNL at Uhealth tower and Jackson Memorial Hospitals, focusing on their blood profiles before and after the procedure.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are scheduled for percutaneous nephrolithotomy and are not currently immunosuppressed.
Not a fit: Patients who are under 18 years of age or currently immunosuppressed will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved patient outcomes by allowing for better risk assessment and management of infections following kidney stone surgery.
How similar studies have performed: While this approach is innovative, similar studies focusing on endotoxin levels and infection risk in surgical settings have shown promise, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults that is able to consent (≥ 18 years of age) * Scheduled to undergo PCNL at Uhealth tower and Jackson Memorial Hospitals * not currently immunosuppressed \[White blood count (WBC) \>= 2, not on immunosuppressive medications\] Exclusion Criteria: * unable to consent and \< 18 years of age * currently immunosuppressed (WBC \< 2, not on immunosuppressive medications)
Where this trial is running
Miami, Florida
- University of Miami — Miami, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Hemendra N Shah — University of Miami
- Study coordinator: Hemendra N Shah
- Email: hns35@miami.edu
- Phone: 3052433246
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.